1.Vitamin D Levels in Patients with Low-energy Hip Fractures
Jaehwi HAN ; Youngho CHO ; Seungmin JEE ; Seongwoo JO
Hip & Pelvis 2020;32(4):192-198
Purpose:
To evaluate serum 25(OH) vitamin D levels in patients with low-energy hip fractures.
Materials and Methods:
Among 983 patients who underwent hip fracture surgery between August 2013 and March 2019, 732 patients were evaluated. The remaining patients were excluded due to the presence of one or more of the following: metastatic bone tumor, metabolic bone disease other than osteoporosis, fracture due to high-energy injury, atypical femoral fracture, and no blood test. We collected patient’s data about age, sex male female, date of injury, a place of residence, fracture type, preinjury ambulation ability according to their Koval score, and their serum level of 25(OH) vitamin D. The mean age was 79.3 years (60-104 years). The sample was comprised of 530 female and 202 male, of which 342 had femoral neck fractures and 390 had trochanteric fractures.
Results:
Of the total 732 patients, 346 patients (47.3%) had a 25(OH) vitamin D level of less than 10 ng/mL, 264 patients (36.1%) had scores of 10-19.9 ng/mL, 87 patients (11.9%) had scores of 20-29.9 ng/mL, and 35 patients (4.8%) had a level higher than 30 ng/mL. Vitamin D deficiency (less than 20 ng/mL) was present in 610 patients (83.3%), insufficiency (20-29.9 ng/mL) was found in 87 patients (11.9%), and 35 patients (4.8%) had normal vitamin D levels. The differences in vitamin D concentration based on season and fracture type were statistically significant.
Conclusion
Vitamin D deficiency and inadequacy were high in patients with low-energy hip fractures, with only 4.9% of patients had normal vitamin D levels. These findings suggest that efforts should be made to maintain proper vitamin D concentration.
2.Temporal Trends of Hospitalized Patients with Heart Failure in Korea.
Jong Chan YOUN ; Seongwoo HAN ; Kyu Hyung RYU
Korean Circulation Journal 2017;47(1):16-24
Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality and rapidly expanding health care costs. The number of HF patients is increasing worldwide and Korea is no exception. Temporal trends of four representative Korean hospitalized HF registries–the Hallym HF study, the Korean Multicenter HF study, the Korean Heart Failure (KorHF) registry and the Korean Acute Heart Failure (KorAHF) registry showed mild survival improvement reflecting overall HF patient care development in Korea despite the increased severity of enrolled patients with higher incidence of multiple comorbidities. Moreover, device therapies such as implantable cardioverter defibrillator and cardiac resynchronization therapy and definitive treatment such as heart transplantation have been increasing in Korea as well. To prevent HF burden increase, it is essential to set up long term effective prevention strategies for better control of ischemic heart disease, hypertension and diabetes, which might be risk factors for HF development. Moreover, proper HF guidelines, performance measures, and performance improvement programs might be necessary to limit HF burden as well.
Cardiac Resynchronization Therapy
;
Cardiovascular Diseases
;
Comorbidity
;
Defibrillators
;
Health Care Costs
;
Heart Failure*
;
Heart Transplantation
;
Heart*
;
Hospitalization
;
Humans
;
Hypertension
;
Incidence
;
Korea*
;
Mortality
;
Myocardial Ischemia
;
Patient Care
;
Prevalence
;
Risk Factors
3.Toward a New Heart Failure Registry in Korea.
Jong Chan YOUN ; Seongwoo HAN ; Kyu Hyung RYU
Korean Circulation Journal 2017;47(3):316-317
No abstract available.
Heart Failure*
;
Heart*
;
Korea*
4.Change in rates of prenatal tests for chromosomal abnormality over a 12-year period in women of advanced maternal age.
Soo Min KIM ; Hyun Hee KIM ; You Jung HAN ; June Seek CHOI ; Hyun Mee RYU ; Seongwoo YANG ; Min Hyoung KIM
Obstetrics & Gynecology Science 2018;61(4):453-460
OBJECTIVE: In 2007, the American College of Obstetricians and Gynecologists (ACOG) recommended that all pregnant women be offered screening or diagnostic tests for chromosomal abnormalities regardless of their age. Noninvasive prenatal testing (NIPT) for common chromosomal aneuploidies was introduced as a screening test in case of high-risk pregnancies. We assessed the rates of prenatal tests in women aged 35 years and older. METHODS: A retrospective study was conducted to compare the rates of amniocentesis, chorionic villus sampling (CVS), serum screening, and NIPT from January 2005 through March 2017 in women aged 35 years and older. We divided the initial 12 months after NIPT introduction into 4-month intervals, beginning in April 2016 through March 2017. RESULTS: The rates of amniocentesis were 56% before the ACOG statement, 38% between the ACOG statement and NIPT introduction, and 10% after NIPT introduction (P=0.001). The rates of CVS during the same periods were 0.5%, 2.1%, and 4.3% (P=0.016), respectively. The rates of serum screening were 44.2%, 61.3%, and 55.1% (P=0.049), respectively. During the 3 quarters after NIPT introduction, the rates of amniocentesis were 16.2%, 12.3%, and 7.3% (P=0.002), respectively; the rates of serum screening were 62%, 54%, and 46% (P=0.03), respectively; and the rates of NIPT were 19.9%, 30.3%, and 39.5% (P=0.007), respectively. The rates of CVS over the same periods were not significantly different. CONCLUSION: The ACOG statement and NIPT introduction significantly decreased the rate of amniocentesis in women of advanced maternal age. NIPT also reduced the rate of serum screening.
Amniocentesis
;
Aneuploidy
;
Chorionic Villi Sampling
;
Chromosome Aberrations*
;
Diagnostic Tests, Routine
;
Female
;
Humans
;
Mass Screening
;
Maternal Age*
;
Pregnancy
;
Pregnancy, High-Risk
;
Pregnant Women
;
Prenatal Diagnosis
;
Retrospective Studies
5.Treatment of gestational diabetes diagnosed by the IADPSG criteria decreases excessive fetal growth
Kyoung Hee LEE ; You Jung HAN ; Jin Hoon CHUNG ; Moon Young KIM ; Hyun Mee RYU ; Jin Ha KIM ; Dong Wook KWAK ; Sung Hoon KIM ; Seongwoo YANG ; Minhyoung KIM
Obstetrics & Gynecology Science 2020;63(1):19-26
6.Gender Difference of Blood Pressure Control Rate and Clinical Prognosis in Patients With Resistant Hypertension: Real-World Observation Study
Hyung Joon JOO ; Yunjin YUM ; Yong Hyun KIM ; Jung-Woo SON ; Sung Hea KIM ; Seonghoon CHOI ; Seongwoo HAN ; Mi-Seung SHIN ; Jin-Ok JEONG ; Eung Ju KIM ;
Journal of Korean Medical Science 2023;38(16):e124-
Background:
There are several differences in the clinical course of hypertension due to the biological and social differences between men and women. Resistant hypertension is an advanced disease state, and significant gender difference could be expected, but much has not been revealed yet. The purpose of this study was to compare gender differences on the current status of blood pressure (BP) control and clinical prognosis in patients with resistant hypertension.
Methods:
This is a multicenter, retrospective cohort study using common data model databases of 3 tertiary hospitals in Korea. Total 4,926 patients with resistant hypertension were selected from January 2017 to December 2018. Occurrence of dialysis, heart failure (HF) hospitalization, myocardial infarction, stroke, dementia or all-cause mortality was followed up for 3 years.
Results:
Male patients with resistant hypertension were younger but had a higher cardiovascular risk than female patients. Prevalence of left ventricular hypertrophy and proteinuria was higher in men than in women. On-treatment diastolic BP was lower in women than in men and target BP achievement rate was higher in women than in men.During 3 years, the incidence of dialysis and myocardial infarction was higher in men, and the incidence of stroke and dementia was higher in women. After adjustment, male sex was an independent risk factor for HF hospitalization, myocardial infarction, and all-cause death.
Conclusion
In resistant hypertension, men were younger than women, but end-organ damage was more common and the risk of cardiovascular event was higher. More intensive cardiovascular prevention strategies may be required in male patients with resistant hypertension.
7.The Prognostic Implication of Metabolic Syndrome in Patients with Heart Failure.
Hyun Ju YOON ; Youngkeun AHN ; Kye Hun KIM ; Jong Chun PARK ; Dong Ju CHOI ; Seongwoo HAN ; Eun Seok JEON ; Myung Chan CHO ; Jae Joong KIM ; Byung Su YOO ; Mi Seung SHIN ; In Whan SEONG ; Seok Min KANG ; Yung Jo KIM ; Hyung Seop KIM ; Shung Chull CHAE ; Byung Hee OH ; Myung Mook LEE ; Kyu Hyung RYU
Korean Circulation Journal 2013;43(2):87-92
BACKGROUND AND OBJECTIVES: Metabolic syndrome (MetS) increases the risk of heart failure (HF). The purpose of this study was to identify the prevalence of MetS in patients with HF and determine the syndrome's association with HF in clinical and laboratory parameters. SUBJECTS AND METHODS: A total of 3200 HF patients (67.6+/-14.5 years) enrolled in a nationwide prospective Korea HF Registry between Jan. 2005 and Oct. 2009. Patients were divided into two groups according to the presence or absence of MetS at admission: group I (presence, n=1141) and group II (absence, n=2059). RESULTS: The prevalence of MetS was 35.7% across all subjects and was higher in females (56.0%). The levels of white blood cells, platelets, creatinine, glucose, and cholesterol were significantly higher in group I than in group II. Left ventricular dimension and volume was smaller and ejection fraction was higher in group I than in group II. An ischemic cause of HF was more frequent in group I. The rates of valvular and idiopathic cause were lower in group I than in group II. The rate of mortality was lower in group I than in group II (4.9% vs. 8.3%, p<0.001). CONCLUSION: Despite the increased cardiovascular risks in MetS, MetS was found to be associated with decreased mortality in HF.
Blood Platelets
;
Cholesterol
;
Creatinine
;
Female
;
Glucose
;
Heart
;
Heart Failure
;
Humans
;
Korea
;
Leukocytes
;
Prevalence
;
Prospective Studies
8.Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry.
Dong Ju CHOI ; Seongwoo HAN ; Eun Seok JEON ; Myeong Chan CHO ; Jae Joong KIM ; Byung Su YOO ; Mi Seung SHIN ; In Whan SEONG ; Youngkeun AHN ; Seok Min KANG ; Yung Jo KIM ; Hyung Seop KIM ; Shung Chull CHAE ; Byung Hee OH ; Myung Mook LEE ; Kyu Hyung RYU
Korean Circulation Journal 2011;41(7):363-371
BACKGROUND AND OBJECTIVES: Acute heart failure (AHF) is associated with a poor prognosis and it requires repeated hospitalizations. However, there are few studies on the characteristics, treatment and prognostic factors of AHF. The aims of this study were to describe the clinical characteristics, management and outcomes of the patients hospitalized for AHF in Korea. SUBJECTS AND METHODS: We analyzed the clinical data of 3,200 hospitalization episodes that were recorded between June 2004 and April 2009 from the Korean Heart Failure (KorHF) Registry database. The mean age was 67.6+/-14.3 years and 50% of the patients were female. RESULTS: Twenty-nine point six percent (29.6%) of the patients had a history of previous HF and 52.3% of the patients had ischemic heart disease. Left ventricular ejection fraction (LVEF) was reported for 89% of the patients. The mean LVEF was 38.5+/-15.7% and 26.1% of the patients had preserved systolic function (LVEF > or =50%), which was more prevalent in the females (34.0% vs. 18.4%, respectively, p<0.001). At discharge, 58.6% of the patients received beta-blockers (BB), 53.7% received either angiotensin converting enzyme-inhibitors or angiotensin receptor blockers (ACEi/ARB), and 58.4% received both BB and ACEi/ARB. The 1-, 2-, 3- and 4-year mortality rates were 15%, 21%, 26% and 30%, respectively. Multivariate analysis revealed that advanced age {hazard ratio: 1.023 (95% confidence interval: 1.004-1.042); p=0.020}, a previous history of heart failure {1.735 (1.150-2.618); p=0.009}, anemia {1.973 (1.271-3.063); p=0.002}, hyponatremia {1.861 (1.184-2.926); p=0.007}, a high level of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) {3.152 (1.450-6.849); p=0.004} and the use of BB at discharge {0.599 (0.360-0.997); p=0.490} were significantly associated with total death. CONCLUSION: We present here the characteristics and prognosis of an unselected population of AHF patients in Korea. The long-term mortality rate was comparable to that reported in other countries. The independent clinical risk factors included age, a previous history of heart failure, anemia, hyponatremia, a high NT-proBNP level and taking BB at discharge.
Anemia
;
Angiotensin Receptor Antagonists
;
Angiotensins
;
Female
;
Heart
;
Heart Failure
;
Hospitalization
;
Humans
;
Hyponatremia
;
Korea
;
Multivariate Analysis
;
Myocardial Ischemia
;
Natriuretic Peptide, Brain
;
Peptide Fragments
;
Prognosis
;
Registries
;
Risk Factors
;
Stroke Volume
9.Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling.
Suk Won CHOI ; Seongwoo HAN ; Wan Joo SHIM ; Dong Ju CHOI ; Yong Jin KIM ; Byung Su YOO ; Kyung Kuk HWANG ; Hui kyung JEON ; Mi Seung SHIN ; Kyu Hyung RYU
Journal of Korean Medical Science 2018;33(25):e171-
BACKGROUND: We aimed to evaluate effect of heart rate (HR) reduction on left ventricular reverse remodeling (LVRR) in Korean patients with heart failure with reduced ejection fraction (HFrEF). METHODS: Ambulatory patients with HFrEF, who had paired echocardiograms, N-terminal prohormone brain natriuretic peptide (NT-proBNP), and global assessment score (GAS) at baseline and 6-month (n = 157), were followed up on preset treatment schedule with bisoprolol. RESULTS: The LVRR occurred in 49 patients (32%) at 6-month. In multivariable analysis, independent predictors associated with LVRR were use of anti-aldosterone agent (odds ratio [OR], 4.18; 95% confidence interval [CI], 1.80–9.71), young age (OR, 0.96; 95% CI, 0.92–0.99), high baseline HR (OR, 3.76; 95% CI, 1.40–10.10), and favorable baseline GAS (OR, 1.73; 95% CI, 1.06–2.81). Beneficial effect of bisoprolol, in terms of LVRR, NT-proBNP, and GAS, was remarkable in the high HR group (baseline HR ≥ 75 beats per minute [bpm]), which showed a large HR reduction. CONCLUSION: High baseline HR (≥ 75 bpm) showed an association with LVRR and improvement of NT-proBNP and GAS in patients with HFrEF. This seems to be due to a large HR reduction after treatments with bisoprolol. Trial registry at www.ClinicalTrials.gov, NCT00749034.
Appointments and Schedules
;
Bisoprolol*
;
Heart Failure
;
Heart Rate*
;
Heart*
;
Humans
;
Natriuretic Peptide, Brain